Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
gp100 Peptide Vaccine in Primary Melanoma
NCT00003895Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Apr 1999
- Primary completion
- Sep 2013
- Modality
- Modified Peptides, Vaccines & Immunotherapeutics, Native Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of gp100:209-217(210M) in melanoma (2 arms), sponsored by National Cancer Institute. Primary endpoints: Toxicity of administration at 6 months, T-cell response to gp100 peptide at 6 months and 4 more. Started Apr 1999; status: completed.
02
Drugs
gp100:209-217(210M)
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT00003895.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00003895.